Form 4: Adverum Biotechnologies' Chief Medical Officer Granted Stock Options

Rabia Gurses Ozden, Chief Medical Officer of Adverum Biotechnologies, was granted stock options to purchase 85,000 shares of common stock on June 17, 2024.

Summary

• Rabia Gurses Ozden, the Chief Medical Officer of Adverum Biotechnologies, Inc., was granted stock options on June 17, 2024.
• The options allow her to purchase 85,000 shares of Adverum's common stock at an exercise price of $7.32 per share.
• The options vest over four years, starting with 25% vesting on the first anniversary of June 10, 2024, and the remainder vesting monthly thereafter.
• John Rakow, acting as Attorney-in-Fact, signed the Form 4 on behalf of Rabia Gurses Ozden on June 20, 2024.
• A power of attorney was executed on March 15, 2024, granting certain officers of Adverum Biotechnologies the authority to act on behalf of Rabia Gurses Ozden for SEC filings related to her holdings in the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive as it indicates continued investment in key personnel.

Positives

• The granting of stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options to align executive incentives with shareholder value.
• The vesting schedule of these options is fairly standard, with many companies using a four-year vesting period with a one-year cliff.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's long-term success.
• Employees may see this as a positive sign of investment in leadership.

Key Dates